---
title: "Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688443.SH.md"
symbol: "688443.SH"
name: "Chongqing Genrix Biopharmaceutical Co., Ltd."
industry: "Biotechnology"
---

# Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | CN Market |
| Website | [www.genrixbio.com](https://www.genrixbio.com) |

## Company Profile

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecifi...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:10.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 37 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1560.46% |  |
| Net Profit YoY | 25.13% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.82 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10.41B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 225.16M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -28.18% | E |
| Profit Margin | -259.16% | E |
| Gross Margin | 97.24% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1560.46% | A |
| Net Profit YoY | 25.13% | B |
| Total Assets YoY | -7.18% | D |
| Net Assets YoY | -24.03% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -38.59% | D |
| OCF YoY | 1560.46% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.07 | E |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 41.28% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Chongqing Genrix Biopharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-28.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-259.16%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "97.24%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1560.46%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "25.13%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.18%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-24.03%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-38.59%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "1560.46%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.07",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "41.28%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BeOne Medicines (SH.688235) | C | A | B | C | A | B |
| 02 | Gan & Lee (SH.603087) | B | B | D | A | B | B |
| 03 | Sunshine Guojian Pharmaceutical (SH.688336) | A | B | D | B | C | B |
| 04 | Biocytogen (SH.688796) | A | A | C | D | B | B |
| 05 | BTBP (SH.600161) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -17.83 | 50/83 | - | - | - |
| PB | 5.82 | 56/83 | 6.12 | 5.68 | 5.00 |
| PS (TTM) | 46.22 | 78/83 | 247.55 | 196.68 | 46.93 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-03T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 28.38 |
| Highest Target | 40.00 |
| Lowest Target | 40.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/688443.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688443.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688443.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.